Abstract
An enormous body of literature has accumulated over the past 15 years implicating apoptosis (programmed cell death) in breast cancer cell death induced by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key components of apoptotic pathways are either entering or will soon enter clinical trials in patients, raising hopes that the information gained from the preclinical studies can be translated to improve patient care. However, there is a new appreciation for the fact that apoptosis is not the only relevant pathway that mediates physiological cell death, and many investigators are challenging the notion that targeting apoptosis is the best means of optimizing therapeutic efficacy in primary tumors. Here I will review some of the basic concepts that have emerged from the study of apoptosis in preclinical models, the evidence that apoptosis does or does not mediate the effects of current front line therapies in patients, and the new strategies that are emerging that are designed to more directly target apoptotic pathways.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239–257.
Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68:251–306.
Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284:555–556.
Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44:817–829.
Conradt B, Horvitz HR. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 1998; 93:519–529.
Ellis RE, Horvitz HR. Two C. elegans genes control the programmed deaths of specific cells in the pharynx. Development 1991; 112:591–603.
Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992; 356:494–499.
Yuan J, Shaham S, Ledoux S et al. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993; 75:641–652.
Alnemri ES, Livingston DJ, Nicholson DW et al. Human ICE/CED-3 protease nomenclature. Cell 1996; 87:171.
Zou H, Henzel WJ, Liu X et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90:405–413.
Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479–489.
Zou H, Li Y, Liu X et al. An APAF-1. cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274:11549–11556.
Samali A, Zhivotovsky B, Jones D et al. Apoptosis: Cell death defined by caspase activation. Cell Death Differ 1999; 6:495–496.
Yoshida H, Kong YY, Yoshida R et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998; 94:739–750.
Hao Z, Duncan GS, Chang CC et al. Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis. Cell 2005; 121:579–591.
Kuida K, Zheng TS, Na S et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996; 384:368–372.
Kuida K, Haydar TF, Kuan CY et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998; 94:325–337.
Zheng TS, Hunot S, Kuida K et al. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med 2000; 6:1241–1247.
Korfali N, Ruchaud S, Loegering D et al. Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis. J Biol Chem 2004; 279:1030–1039.
Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993; 67:2168–2174.
Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and iap. Mol Cell Biol 1994; 14:5212–5222.
Miller LK. An exegesis of IAPs: Salvation and surprises from BIR motifs. Trends Cell Biol 1999; 9:323–328.
Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death’s door. Nat Rev Mol Cell Biol 2002; 3:401–410.
Tenev T, Zachariou A, Wilson R et al. IAPs are functionally nonequivalent and regulate effector caspases through distinct mechanisms. Nat Cell Biol 2005; 7:70–77.
White K, Grether ME, Abrams JM et al. Genetic control of programmed cell death in Drosophila. Science 1994; 264:677–683.
Grether ME, Abrams JM, Agapite J et al. The head involution defective gene of Drosophila melanogaster functions in programmed cell death. Genes Dev 1995; 9:1694–1708.
Chen P, Nordstrom W, Gish B et al. Grim, a novel cell death gene in Drosophila. Genes Dev 1996; 10:1773–1782.
Zachariou A, Tenev T, Goyal L et al. IAP-antagonists exhibit nonredundant modes of action through differential DIAP1 binding. EMBO J 2003; 22:6642–6652.
Du C, Fang M, Li Y et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33–42.
Verhagen AM, Ekert PG, Pakusch M et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102:43–53.
Ekert PG, Silke J, Hawkins CJ et al. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J Cell Biol 2001; 152:483–490.
Pegoraro L, Palumbo A, Erikson J et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 1984; 81:7166–7170.
McDonnell TJ, Deane N, Platt FM et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57:79–88.
Hanada M, Delia D, Aiello A et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82:1820–1828.
McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52:6940–6944.
Buchholz TA, Davis DW, McConkey DJ et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003; 9:33–41.
Johnston SR, MacLennan KA, Sacks NP et al. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994; 30A:1663–1669.
Nathan B, Gusterson B, Jadayel D et al. Expression of Bcl-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol 1994; 5:409–414.
Bhargava V, Kell DL, van de Rijn M et al. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994; 145:535–540.
Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145:1191–1198.
Gee JM, Robertson JF, Ellis IO et al. Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59:619–628.
Olopade OI, Adeyanju MO, Safa AR et al. Overexpression of Bcl-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997; 3:230–237.
Martin SS, Ridgeway AG, Pinkas J et al. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 2004; 23:4641–4645.
Romieu-Mourez R, Kim DW, Shin SM et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003; 23:5738–5754.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917–921.
Tamm I, Wang Y, Sausville E et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58:5315–5320.
Yang L, Cao Z, Yan H et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res 2003; 63:6815–6824.
Tanaka K, Iwamoto S, Gon G et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6:127–134.
Kennedy SM, O’Driscoll L, Purcell R et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88:1077–1083.
Parton M, Krajewski S, Smith I et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 2002; 8:2100–2108.
Distelhorst CW, Berger NA. Glucocorticoid-induced DNA fragmentation in acute lymphoblastic leukemia cells. Trans Assoc Am Physicians 1988; 101:114–124.
Distelhorst CW. Glucocorticosteroids induce DNA fragmentation in human lymphoid leukemia cells. Blood 1988; 72:1305–1309.
Dowd DR, MacDonald PN, Komm BS et al. Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J Biol Chem 1991; 266:18423–18426.
Lam M, Dubyak G, Distelhorst CW. Effect of glucocorticosteroid treatment on intracellular calcium homeostasis in mouse lymphoma cells. Mol Endocrinol 1993; 7:686–693.
Lam M, Dubyak G, Chen L et al. Evidence that Bcl-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci USA 1994; 91:6569–6573.
Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 1989; 49:5870–5878.
Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40:2353–2362.
Eastman A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 1990; 2:275–280.
Potten CS. Extreme sensitivity of some intestinal crypt cells to X and gamma irradiation. Nature 1977; 269:518–521.
Zhivotovsky BD, Zvonareva NB, Hanson KP. Characteristics of rat thymus chromatin degradation products after whole-body x-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 1981; 39:437–440.
Hanson KP, Zhivotovsky BD. Effects of X-irradiation on the hybridization of rat thymus nuclear RNA with repeated and unique DNA sequences. Int J Radiat Biol Relat Stud Phys Chem Med 1976; 30:129–139.
Stephens LC, Ang KK, Schultheiss TE et al. Apoptosis in irradiated murine tumors. Radiat Res 1991; 127:308–316.
Mirkovic N, Voehringer DW, Story MD et al. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 1997; 15:1461–1470.
Lowe SW, Schmitt EM, Smith SW et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847–849.
Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849–852.
Evan G. Cancer—a matter of life and cell death. Int J Cancer 1997; 71:709–711.
Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Genet Dev 1994; 4:120–129.
Lowe SW, Ruley HE, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957–967.
Evan GI, Wyllie AH, Gillbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119–128.
Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 2003; 13:77–83.
Hueber AO, Evan GI. Traps to catch unwary oncogenes. Trends Genet 1998; 14:364–367.
Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88–91.
Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807–810.
Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002; 9:183–195.
Chang J, Ormerod M, Powles TJ et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000; 89:2145–2152.
Symmans WF, Volm MD, Shapiro RL et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6:4610–4617.
Symmans FW. Breast cancer response to paclitaxel in vivo. Drug Resist Updat 2001; 4:297–302.
Davis DW, Buchholz TA, Hess KR et al. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: Early assessment predicts clinical response. Clin Cancer Res 2003; 9:955–960.
Blankenberg FG, Katsikis PD, Tait JF et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95:6349–6354.
Louie AY, Huber MM, Ahrens ET et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18:321–325.
Walker NI, Bennett RE, Kerr JF. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat 1989; 185:19–32.
Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+−Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 1988; 13:103–117.
English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989; 15:233–250.
Soule HD, McGrath CM. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett 1980; 10:177–189.
Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 30:311–314.
Kyprianou N, English HF, Davidson NE et al. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991; 51:162–166.
Rodrik V, Zheng Y, Harrow F et al. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 2005; 25:7917–7925.
Brodie A, Jelovac D, Macedo L et al. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 2005; 11:884s–888s.
Janicke RU, Sprengart ML, Wati MR et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273:9357–9360.
Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11:951s–958s.
Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365:60–62.
Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359:2131–2139.
Osborne CK, Schiff R. Estrogen-receptor biology: Continuing progress and therapeutic implications. J Clin Oncol 2005; 23:1616–1622.
Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177–182.
Yu D, Jing T, Liu B et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998; 2:581–591.
Yu D, Liu B, Tan M et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996; 13:1359–1365.
Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997; 57:1199–1205.
Yang W, Klos K, Yang Y et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94:2855–2861.
Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003; 98:1377–1385.
Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26:60–70.
Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118–129.
Dieras V, Beuzeboc P, Laurence V et al. Interaction between Herceptin and taxanes. Oncology 2001; 61(Suppl 2):43–49.
Emens LA, Davidson NE. Trastuzumab in breast cancer. Oncology (Williston Park) 2004; 18:1117–1128, (discussion 1131–1112, 1137–1118).
Stern DF. ErbBs in mammary development. Exp Cell Res 2003; 284:89–98.
Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000; 2:176–183.
DiGiovanna MP, Stern DF, Edgerton SM et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 23:1152–1160.
Dublin EA, Barnes DM, Wang DY et al. TGF alpha and TGF beta expression in mammary carcinoma. J Pathol 1993; 170:15–22.
Ito Y, Takeda T, Higashiyama S et al. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001; 67:81–85.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550–6565.
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787–2799.
Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11:865s–870s.
Johnston SR. Combinations of endocrine and biological agents: Present status of therapeutic and presurgical investigations. Clin Cancer Res 2005; 11:889s–899s.
Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: A phase III trial—INTACT 2. J Clin Oncol 2004; 22:785–794.
Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: A phase III trial—INTACT 1. J Clin Oncol 2004; 22:777–784.
Solit DB, She Y, Lobo J et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005; 11:1983–1989.
Griffith TS, Lynch DH. TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10:559–563.
Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333–339.
Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818–821.
Pan G, O’Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111–113.
Chinnaiyan AM, O’Rourke K, Tewari M et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81:505–512.
Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death—inducing signaling complex. Cell 1996; 85:817–827.
Fernandes-Alnemri T, Armstrong RC, Krebs J et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 1996; 93:7464–7469.
Kischkel FC, Hellbardt S, Behrmann I et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14:5579–5588.
Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17:1675–1687.
Li H, Zhu H, Xu CJ et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491–501.
Luo X, Budihardjo I, Zou H et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94:481–490.
Scorrano L, Ashiya M, Buttle K et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell 2002; 2:55–67.
Wilkinson JC, Cepero E, Boise LH et al. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell Biol 2004; 24:7003–7014.
Kamradt MC, Lu M, Werner ME et al. The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 2005; 280:11059–11066.
Kamradt MC, Chen F, Sam S et al. The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 2002; 277:38731–38736.
Kamradt MC, Chen F, Cryns VL. The small heat shock protein alpha B-crystallin negatively regulates cytochrome c-and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 2001; 276:16059–16063.
Buchsbaum DJ, Zhou T, Grizzle WE et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9:3731–3741.
Georgakis GV, Li Y, Humphreys R et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death. Br J Haematol 2005; 130:501–510.
Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1:82–89.
Lashinger LM, Zhu K, Williams SA et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005; 65:4902–4908.
Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta 1999; 1489:97–106.
Klasa RJ, Gillum AM, Klem RE et al. Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12:193–213.
Kim R, Tanabe K, Emi M et al. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 2005; 103:2199–2207.
Banerjee D. Genasense (Genta Inc). Curr Opin Investig Drugs 2001; 2:574–580.
Tolcher AW, Chi K, Kuhn J et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11:3854–3861.
Badros AZ, Goloubeva O, Rapoport AP et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005; 23:4089–4099.
Frantz S. Lessons learnt from Genasense’s failure. Nat Rev Drug Discov 2004; 3:542–543.
Chao DT, Linette GP, Boise LH et al. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182:821–828.
Kagawa S, Pearson SA, Ji L et al. A binary adenoviral vector systems for expressing high levels of the proapoptotic gene bax. Gene Ther 2000; 7:75–79.
Li X, Marani M, Yu J et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 2001; 61:186–191.
Pataer A, Fang B, Yu R et al. Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res 2000; 60:788–792.
Zou Y, Peng H, Zhou B et al. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 2002; 62:8–12.
Chen JS, Liu JC, Shen L et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11:740–747.
Letai A, Bassik MC, Walensky LD et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2:183–192.
Kuwana T, Bouchier-Hayes L, Chipuk JE et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17:525–535.
Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999; 274:13298–13304.
Wang JL, Zhang ZJ, Choksi S et al. Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells. Cancer Res 2000; 60:1498–1502.
Walensky LD, Kung AL, Escher I et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305:1466–1470.
Kitada S, Leone M, Sareth S et al. Discovery, characterization, and structureactivity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003; 46:4259–4264.
Mohammad RM, Wang S, Aboukameel A et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(−)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005; 4:13–21.
Oliver CL, Miranda MB, Shangary S et al. (−)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 2005; 4:23–31.
Tzung SP, Kim KM, Basanez G et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3:183–191.
Chan SL, Lee MC, Tan KO et al. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003; 278:20453–20456.
Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677–681.
Deveraux QL, Takahashi R, Salvesen GS et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388:300–304.
Arkin M. Protein-protein interactions and cancer: Small molecules going in for the kill. Curr Opin Chem Biol 2005; 9:317–324.
Takahashi R, Deveraux Q, Tamm I et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998; 273:7787–7790.
Sun C, Cai M, Gunasekera AH et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 1999; 401:818–822.
Riedl SJ, Renatus M, Schwarzenbacher R et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001; 104:791–800.
Sun C, Cai M, Meadows RP et al. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000; 275:33777–33781.
Shiozaki EN, Chai J, Rigotti DJ et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003; 11:519–527.
Wu G, Chai J, Suber TL et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408:1008–1012.
Liu Z, Sun C, Olejniczak ET et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408:1004–1008.
Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581–8589.
Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580–584.
Hu Y, Cherton-Horvat G, Dragowska V et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9:2826–2836.
Arnt CR, Chiorean MV, Heldebrant MP et al. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277:44236–44243.
Yang L, Mashima T, Sato S et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in nonsmall cell lung cancer H460 cells: Therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 2003; 63:831–837.
Sun H, Nikolovska-Coleska Z, Yang CY et al. Structurebased design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem 2004; 47:4147–4150.
Sun H, Nikolovska-Coleska Z, Yang CY et al. Structurebased design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 2004; 126:16686–16687.
Oost TK, Sun C, Armstrong RC et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47:4417–4426.
Fulda S, Wick W, Weller M et al. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8:808–815.
Wu TY, Wagner KW, Bursulaya B et al. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol 2003; 10:759–767.
Nikolovska-Coleska Z, Xu L, Hu Z et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structurebased computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004; 47:2430–2440.
Li L, Thomas RM, Suzuki H et al. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science 2004; 305:1471–1474.
Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307–315.
Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954–2963.
Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22:4217–4226.
Keane MM, Ettenberg SA, Nau MM et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59:734–741.
Chinnaiyan AM, Prasad U, Shankar S et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97:1754–1759.
Nagane M, Pan G, Weddle JJ et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60:847–853.
Ohtsuka T, Buchsbaum D, Oliver P et al. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22:2034–2044.
Xu ZW, Kleeff J, Friess H et al. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 2003; 23:251–258.
Singh TR, Shankar S, Chen X et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003; 63:5390–5400.
Ravi R, Jain AJ, Schulick RD et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004; 64:9105–9114.
Zhang XD, Gillespie SK, Borrow JM et al. The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003; 66:1537–1545.
Rosato RR, Almenara JA, Dai Y et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2:1273–1284.
Guo F, Sigua C, Tao J et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64:2580–2589.
Nakata S, Yoshida T, Horinaka M et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23:6261–6271.
Chopin V, Slomianny C, Hondermarck H et al. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors signaling and requires P21(waf1). Ex Cell Res 2004; 298:560–573.
Sonnemann J, Gange J, Kumar KS et al. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 2005; 23:99–109.
Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24:4609–4623.
Vanoosten RL, Moore JM, Karacay B et al. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005; 4.
Sun SY, Yue P, Hong WK et al. Augementation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-03-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60:7149–7155.
Cuello M, Coats AO, Darko I et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004; 11:527–541.
Goke R, Goke A, Goke B et al. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion 2001; 64:75–80.
Kim Y, Suh N, Sporn M et al. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277:22320–22329.
Lu M, Kwan T, Yu C et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280:6742–6751.
Kim DM, Koo SY, Jeon K et al. Rapid induction of apoptosis by combination fo flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003; 63:621–626.
Cuello M, Ettenberg SA, Clark AS et al. Down-regulation of the erbB-2 receptor by trastuzumab (herception) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61:4892–4900.
Sayers TJ, Brooks AD, Koh CY et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102:303–310.
Johnson TR, Stone K, Nikrad M et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22:4953–4963.
An J, Sun YP, Adams J et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003; 9:4537–4545.
Yin D, Zhou H, Kumagai T et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastome multiforme (GBM). Oncogene 2005; 24:344–354.
Papageorgiou A, Lashinger L, Millikan R et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004; 64:8973–8979.
Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005; 4:77–82.
Nikrad M, Johnson T, Puthalalath H et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005; 4:443–449.
Bai J, Sui J, Demirijan A et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: Tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65:2344–2352.
Nencioni A, Wille L, Dal Bello G et al. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 2005; 11:4259–4265.
Zhu H, Guo W, Zhang L et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005; 4.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
McConkey, D.J. (2007). Therapy-Induced Apoptosis in Primary Tumors. In: Yu, D., Hung, MC. (eds) Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, vol 608. Springer, New York, NY. https://doi.org/10.1007/978-0-387-74039-3_3
Download citation
DOI: https://doi.org/10.1007/978-0-387-74039-3_3
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-74037-9
Online ISBN: 978-0-387-74039-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)